Daniel Podzamczer

3.5k total citations
35 papers, 821 citations indexed

About

Daniel Podzamczer is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Daniel Podzamczer has authored 35 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Infectious Diseases, 16 papers in Virology and 12 papers in Epidemiology. Recurrent topics in Daniel Podzamczer's work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (16 papers). Daniel Podzamczer is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (16 papers). Daniel Podzamczer collaborates with scholars based in Spain, United States and United Kingdom. Daniel Podzamczer's co-authors include Xavier Badı́a, Peré Domingo, José M. Peña, Juan Tiraboschi, Esteban Ribera, Estebán Martínez, Jaime Cosín, J. Alberdi, Xavier Claramonte and Miguel Santín and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Daniel Podzamczer

34 papers receiving 784 citations

Peers

Countries citing papers authored by Daniel Podzamczer

Since Specialization

Citations

This map shows the geographic impact of Daniel Podzamczer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Podzamczer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Podzamczer more than expected).

Fields of papers citing papers by Daniel Podzamczer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Podzamczer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Podzamczer. The network helps show where Daniel Podzamczer may publish in the future.

Co-authorship network of co-authors of Daniel Podzamczer

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Podzamczer. A scholar is included among the top collaborators of Daniel Podzamczer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Podzamczer. Daniel Podzamczer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV 2023 ·Clinica Chimica Acta ·Raül Rigo‐Bonnin, (unknown), (unknown), Arkaitz Imaz, Juan Tiraboschi, (unknown), Jordí Niubó, (unknown), Daniel Podzamczer	2
2	Short-term Neuropsychiatric and Body Weight Changes in PatientsSwitching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69) 2022 ·Current HIV Research ·Juan Tiraboschi, Paula Prieto, María Saumoy, (unknown), Arkaitz Imaz, (unknown), (unknown), (unknown), (unknown), Daniel Podzamczer	3
3	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV–1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58) 2020 ·Clinical Infectious Diseases ·Arkaitz Imaz, Juan Tiraboschi, Jordí Niubó, Javier Martínez‐Picado, Mackenzie L. Cottrell, Peré Domingo, Iván Chivite, Eugènia Negredo, Amanda P. Schauer, (unknown), Sandra Morenilla, Víctor Urrea, (unknown), (unknown), Benito García, Angela D. M. Kashuba, Daniel Podzamczer	14
4	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption 2019 ·PLoS ONE ·Jürgen K. Rockstroh, David M. Asmuth, Giuseppe Pantaleo, Bonaventura Clotet, Daniel Podzamczer, Jan van Lunzen, Keikawus Arastéh, Ronald T. Mitsuyasu, Barry Peters, Silvia Nozza, (unknown), Mats Ökvist, Kim Krogsgaard, Maja A. Sommerfelt	7
5	DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI 2014 ·Journal of the International AIDS Society ·(unknown), José Moltó, Elena Ferrer, Adrián Curran, Laura Else, Bonaventura Clotet, Juan Tiraboschi, Jordí Niubó, Antonia Vila, Daniel Podzamczer	4
6	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Eugènia Negredo, Peré Domingo, Elena Ferrer, Vicente Estrada, Adrián Curran, (unknown), Valentina Isernia, (unknown), Núria Pérez‐Álvarez, Jordi Puig, Anna Bonjoch, Patricia Echeverría, Daniel Podzamczer, Bonaventura Clotet	25
7	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function 2012 ·Antiviral Therapy ·Arkaitz Imaz, Montserrat Olmo, María Luz Pintos Peñaranda, Félix Gutiérrez, Joan Romeu, María Larrousse, Peré Domingo, José A. Oteo, Jordi Curto, (unknown), Mar Masiá, José López‐Aldeguer, José Antonio Iribarren, Daniel Podzamczer, (unknown)	16
8	Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Donna Mildvan, Daniel Podzamczer, Gerd Fätkenheuer, Manuel Leal, (unknown), Srinivas Rao Valluri, Charles Craig, Lynn McFadyen, Manoli Vourvahis, Jayvant Heera, Hernán Valdez, Alex R. Rinehart, Simon Portsmouth	30
9	Fatal Bacillary Angiomatosis Mimicking An Infiltrative Vascular Tumour in the Immune Restoration Phase of An HIV-Infected Patient 2011 ·Antiviral Therapy ·Óscar Murillo, (unknown), (unknown), Horacio Gil, Pedro Anda, (unknown), Daniel Podzamczer	3
10	Visceral Leishmaniasis Treated with Antimonials/Paromomycin followed by Itraconazole/Miltefosine after Standard Therapy Failures in a Human Immunodeficiency Virus–Infected Patient 2010 ·American Journal of Tropical Medicine and Hygiene ·(unknown), Rogelio López‐Vélez, Montserrat Olmo, Daniel Podzamczer	11
11	Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Juan Tiraboschi, Jordí Niubó, Jordi Curto, Daniel Podzamczer	29
12	Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Ángeles Jaén, Anna Esteve, Josep M. Miró, Cristina Tural, Alexandra Montoliu, Elena Ferrer, Melcior Riera, Ferrán Segura, Lluís Force, Omar Sued, Josep Vilaró, Felipe García, Àngels Masabeu, Jordi Altés, Bonaventura Clotet, Daniel Podzamczer, Javier Murillas, Gemma Navarro, Josep M. Gatell, Jordi Casabona	44
13	Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Vicenç Falcó, Montserrat Olmo, S Villar del Saz, Ana Guelar, José Ramón Santos, Mar Gutiérrez, (unknown), Elisabet Deig, Gràcia Mateo, M. Montero, Enric Pedrol, Daniel Podzamczer, Peré Domingo, Josep M. Llibre	60
14	Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIV‐Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial 2006 ·Clinical Infectious Diseases ·José M. Miró, Juan Carlos López, Daniel Podzamczer, José M. Peña, J. Alberdi, Estebán Martínez, Peré Domingo, Jaime Cosín, Xavier Claramonte, José Ramón Arribas, Miguel Santín, Esteban Ribera, (unknown)	26
15	Validación del cuestionario de satisfacción con el tratamiento antirretroviral: cuestionario CESTA 2005 ·Enfermedades Infecciosas y Microbiología Clínica ·Emilia Condés, Koldo Aguirrebengoa, David Dalmau, José Manuel Márquez Estrada, Luís Force, Miguel Górgolas, Xavier Badía, Daniel Podzamczer	9
16	Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma 2004 ·AIDS ·Luz Martı́n-Carbonero, Ana Barrios, Pere Saballs, Guillem Sirera, Jesús Santos, (unknown), Eulalia Valencia, Marta Alegre, Daniel Podzamczer, Juan González‐Lahoz	73
17	Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin 2001 ·AIDS ·Santiago Moreno, Daniel Podzamczer, (unknown), José Antonio Iribarren, Elena Ferrer, Jesús Repáraz, José M. Peña, Esther Cabrero, Luis Usán	26
18	A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection 2001 ·New England Journal of Medicine ·Juan Carlos López Bernaldo de Quirós, José M. Miró, José M. Peña, Daniel Podzamczer, J. Alberdi, Estebán Martínez, Jaime Cosín, Xavier Claramonte, Juan González, Peré Domingo, José L. Casado, Esteban Ribera	117
19	Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin 2000 ·AIDS ·Marina Núñez, Ana Machuca, Vincent Soriano, Daniel Podzamczer, Juan González‐Lahoz	19
20	Cytomegalovirus Ventriculoencephalitis in AIDS Patients 1995 ·Scandinavian Journal of Infectious Diseases ·Albert Salazar, Daniel Podzamczer, Ramón Reñé, Miguel Santín, José L. Pérez, Isidró Ferrer, P Fernández-Viladrich, Francesc Gudiol	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact